Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer

Zalba, Sara; López-Contreras, Ana M.; Haeri, Azadeh; Hagen, Timo L.M. ten; Navarro, Íñigo; Koning, Gerben A.; Garrido, María J.

doi:10.1016/j.jconrel.2015.05.271

Cited by 100 publications

(50 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Garrido et al developed an EGFR-targeted, oxaliplatin incorporated liposome for the treatment of EGFR-expressing wild-type KRAS metastatic colorectal cancer. 107 Compared to the free oxaliplatin or non-targeted liposomes, liposomes with cetuximab linked to the surface demonstrated up to a 3-fold higher level of intracellular drug delivery in cells overexpressing EGFR in CRC xenograft bearing mice. Moreover, EGFR targeted oxaliplatin incorporated liposomes were also effective in oxaliplatin resistant cell lines, indicating such targeted liposomes to be a promising novel nanomedicine for CRC treatment.…”

Section: -105mentioning

confidence: 98%

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: -105mentioning

confidence: 98%

Polymeric nanoparticles for colon cancer therapy: overview and perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The avidin caps were cleaved only by these proteinase, and therefore controlled release and synergistic therapeutic effects were observed in vitro and ex vivo. To treat EGFR-expressing wild-type KRAS metastatic colorectal cancer, oxaliplatin was incorporated into liposomes conjugated with cetuximab on the surface [170]. Liposomes with cetuximab linked to the surface demonstrated up to a 3-fold higher level of intracellular drug delivery in cells overexpressing EGFR.…”

Section: Optimal Design Of Delivery Systems For Combination Therapymentioning

confidence: 99%

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp

Shim

Heo

et al. 2016

Advanced Drug Delivery Reviews

440

258

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oThe dynamic and versatile nature of diseases such as cancer has been a pivotal challenge for developing efficient and safe therapies. Cancer treatments using a single therapeutic agent often result in limited clinical outcomes due to tumor heterogeneity and drug resistance. Combination therapies using multiple therapeutic modalities can synergistically elevate anti-cancer activity while lowering doses of each agent, hence, reducing side effects. Co-administration of multiple therapeutic agents requires a delivery platform that can normalize pharmacokinetics and pharmacodynamics of the agents, prolong circulation, selectively accumulate, specifically bind to the target, and enable controlled release in target site. Nanomaterials, such as polymeric nanoparticles, gold nanoparticles/cages/shells, and carbon nanomaterials, have the desired properties, and they can mediate therapeutic effects different from those generated by small molecule drugs (e.g., gene therapy, photothermal therapy, photodynamic therapy, and radiotherapy). This review aims to provide an overview of developing multi-modal therapies using nanomaterials ("combo" nanomedicine) along with the rationale, up-to-date progress, further considerations, and the crucial roles of interdisciplinary approaches.

show abstract

“…The combination of 5-FU/LV with either irinotecan or oxaliplatinhas has been used as first-line and second-line treatment to offer a significant survival benefit for patients with unresectable CLMs [11,12]. Moreover, the addition of new targeted agents has brought further increases in antitumor activity [13,14]. Nevertheless, in case of disease progression after two lines of SCT, treatment options for patients are limited.…”

Section: Discussionmentioning

confidence: 99%